Alectinib hydrochloride NEW
| Price | $37 | $51 | $77 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Alectinib hydrochloride | CAS No.: 1256589-74-8 |
| Purity: 99.96% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Alectinib hydrochloride |
| Description | Alectinib hydrochloride (RO5424802 Hydrochloride) is a selective, and orally available inhibitor of ALK( IC50 : 1.9 nM) |
| Animal Research | Animal Model:SCID or nude mice bearing NCI-H2228 cells. Dosage:0.2 mg/kg, 0.6 mg/kg, 2 mg/kg, 6 mg/kg, 20 mg/kg. Administration:Oral administration; once daily; for 11 days |
| In vivo | Alectinib hydrochloride(CH5424802), a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as nonsmall cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 6.25 mg/mL (12.04 mM), Sonication is recommended. |
| Keywords | Cluster of differentiation 246 | CH-5424802 | RO 5424802 | AF-802 | Alectinib hydrochloride | Alectinib Hydrochloride | inhibit | Inhibitor | AF802 | Alectinib | RO5424802 | RO-5424802 | CH 5424802 | ALK tyrosine kinase receptor | Anaplastic lymphoma kinase | CD246 | CH5424802 | Anaplastic lymphoma kinase (ALK) | AF 802 |
| Inhibitors Related | Lorlatinib | SB-431542 | DMH-1 | RepSox | Crizotinib | Ceritinib | LDN-193189 2HCl | Brigatinib | A 83-01 | ALK-IN-1 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/10mg |
VIP1Y
|
Moxin Chemicals
|
2024-12-16 | |
| $1.00/5g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-06-25 | |
| $0.00/1kg |
Nanjing Fred Technology Co., Ltd
|
2023-11-15 | ||
| $30.00/1KG |
Anhui Ruihan Technology Co., Ltd
|
2023-09-07 | ||
| $0.00/1kg |
VIP5Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-08-16 | |
| $2.00/1kg |
VIP7Y
|
Career Henan Chemical Co
|
2018-12-23 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY